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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
To assess the efficacy of linezolid when used as part of a second-line regimen for treating people with multidrug-resistant (MDR-) and
extensively drug-resistant (XDR-) pulmonary tuberculosis (TB), and to assess the prevalence and severity of adverse events associated
with linezolid use in this patient group.
B A C K G R O U N D
Description of the condition
Tuberculosis (TB) is caused by infection with bacteria of theMy-
cobacterium tuberculosis complex. It remains one of the leading in-
fectious causes of death worldwide despite significant reductions
in incidence; there were 1.4 million deaths from TB worldwide
in 2015, with an additional 0.4 million deaths from TB amongst
people living with human immunodeficiency virus (HIV) (WHO
TB Report 2016). Pulmonary TB is the most common form of
TB, and the most important from a public health point of view
because TB is transmitted by aerosolized droplets from people
with active pulmonary TB when they cough (Vashishtha 2013).
It is estimated that around one third of the world’s population is
infected with TB, although of these only one in ten will develop
active TB disease (WHO 2009).
Most people with TB are infected with strains of M. tuberculosis
that are treatable with the standard first-line drugs recommended
by theWorldHealthOrganization (WHO)guidelines: rifampicin,
isoniazid, pyrazinamide, and ethambutol (WHO 2010). Early di-
agnosis and treatment with effective drugs is one of the mainstays
of TB disease control, as well as being a life-saving intervention
for people with TB.
Multidrug-resistant TB (MDR-TB) is TB disease that is caused
byM. tuberculosis strains that have acquired resistance to two im-
portant drugs in the first-line regimen: rifampicin and isoniazid
(Sharma 2006). Extensively drug-resistant TB (XDR-TB) occurs
when M. tuberculosis strains are resistant to rifampicin, isoniazid,
and any of the antibiotics in the fluoroquinolone class, as well as
any of the three injectable drugs used in the second-line treatment
of TB: amikacin, kanamycin, and capreomycin (WHO 2016).
The WHO estimates that 480,000 cases of MDR-TB occurred in
2015, with 190,000 people dying of MDR-TB worldwide, and
an estimated 9.5% of people with MDR-TB actually have XDR-
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TB (WHO TB Report 2016). Detection of drug-resistant TB is
challenging and currently requires costly laboratory services, and
access to effective treatment is far from universal. Though there
has been rapid progress, only 12% of new TB cases were tested for
drug resistance in 2014, with case detection at only 41% (WHO
2015). Over the last decade treatment success rates have remained
static at around 50% (WHO 2015), and the international TB
community has recognized that new drugs and drug regimens
with improved efficacy are urgently needed to improve cure rates.
The WHO End TB Strategy outlines measures for post-2015 TB
control, including aims to detect and treat everyone with drug-
resistant TB, which will require significant scaling up of resources
and efforts (WHO 2014).
Constructing MDR-TB therapy regimens is recognized as a dif-
ficult balancing act, with several of the agents available being ex-
pensive and toxic, and of uncertain antituberculous efficacy due to
limited evidence from clinical trials (Chang 2013a). This is espe-
cially true for XDR-TB. This has led to efforts being channeled to-
wards investigation of new and existing drugs and regimens, with
a drive to standardize trial design and reporting (Mitnick 2015),
and focus on low-resource settings which are disproportionately
affected by TB and MDR-TB globally (Sloan 2016).
Description of the intervention
The recently updated WHO guidelines for treatment of drug-re-
sistant TB suggest linezolid as a “group C: other core second-line
agent”, and recommend that two such drugs are required within
a core drug-resistant TB regimen (WHO 2016). However, con-
cerns about serious adverse effects prompt the guidelines to state
that, where close monitoring for adverse events is not available,
“linezolid would best be reserved for MDR-TB patients who have
additional drug resistance...or who are intolerant to other compo-
nents of the core regimen” (WHO 2016).
This upgrades the status of linezolid, which in the previous it-
eration of the WHO drug-resistant TB guidelines was a “group
5” drug (WHO 2011). Evidence of efficacy and safety of group
5 drugs was deemed insufficient to recommend their use as core
drugs within a regimen. In fact, the number of cases treated was
so small that the evidence for linezolid was not analysed separately
for the WHO 2011 guidelines.
Subsequent publications have suggested linezolid may have a more
significant role in regimens, especially in the context of XDR-TB.
The International Union Against TB and Lung Disease guidelines
recommend it should be the third drug to consider within group
5 (Caminero 2013).
Three meta-analyses have examined the evidence for linezolid in
drug-resistant TB (Cox 2012; Sotgiu 2012; Zhang 2015). They
include mostly observational data, much of it retrospective, and
few randomized trials have been undertaken. There ismuch debate
surrounding linezolid, without consensus, due to the lack of high
quality evidence. Many suggest it should be more widely used,
hence its upgrade in the recentWHOguidelines (Caminero 2015;
WHO 2016).
Inclusion of retrospective data for treatment outcome may well
have exacerbated the effect of confounders in the meta-analyses of
treatment efficacy (Cox 2012; Sotgiu 2012; Zhang 2015). These
reviews focus on efficacy more than safety, with selection of studies
based on the former. Safety is amajor area of concernwith linezolid
(Ramachandran 2015).
How the intervention might work
Linezolid is an oxazolidinone antibiotic that disrupts protein syn-
thesis by binding to the 70S initiation complex of bacterial ribo-
somes (Sloan 2016). It also binds to human mitochondria and
inhibits protein synthesis, which is the mechanism of toxicity in
clinical use (De Vriese 2006). It is active against most Gram-pos-
itive bacteria, with extensive evidence of in vitro activity against
isolates of M. tuberculosis, including those resistant to first-line
drugs (Erturan 2005; Huang 2008).
Linezolid can be taken orally or intravenously, with excellent oral
bioavailability, and therefore does not require ongoing injections
throughout a regimen (Dryden 2011). Though an adult dose of
600 mg twice daily is most commonly used to treat infections
due to Gram-positive bacteria, a variety of dosing strategies have
been used for linezolid in the context of drug-resistant TB. These
have ranged from 300 mg to 1200 mg, as once- or twice-daily
regimens, and lower doses have been tried in an attempt to increase
tolerability and reduce toxicity (Park 2006; Migliori 2009; Yew
2009; Koh 2012). A thrice-weekly intermittent dosing regimen
has also been tried in limited cohorts to prolong linezolid duration
for as long as possible, with the suggestion of promising outcomes
(Chang 2013b). The optimal dosing and duration of linezolid
remains unclear from the perspective of preventing emergence of
resistance, as well as efficacy, tolerability, and toxicity.
Adverse effects of linezolid include suppression of the bone mar-
row causing anaemia and thrombocytopenia, peripheral neuropa-
thy and optic neuropathy leading to disability and blindness which
is usually irreversible, and most commonly gastrointestinal up-
set which may lead to difficulties with adherence to treatment
(Ramachandran 2015). Adverse events with courses of linezolid
longer than one month appear to be common, affecting over 80%
of participants in some studies (Lee 2012, Tang 2015).
Why it is important to do this review
Uncertainties about the balance between benefits and risks of line-
zolid use in drug-resistant TB mean a systematic review that as-
sesses the efficacy and adverse events related to linezolid is highly
desirable. Its recent inclusion as a core agent in second-line regi-
mens in WHO guidance, with a warning regarding availability of
monitoring for adverse events and lack of firm guidance on dos-
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ing, means that clinicians and policy makers will need an up-to-
date appraisal of the evidence (WHO2016). It should assist policy
makers who are deciding on the place of linezolid in their national
and regional drug-resistant TB programmes, as well as individual
clinicians trying to interpret the wide variety of published data
on how effective, safe, and tolerable linezolid is in people being
treated for MDR-TB and XDR-TB.
O B J E C T I V E S
To assess the efficacy of linezolid when used as part of a second-
line regimen for treating people with multidrug-resistant (MDR-
) and extensively drug-resistant (XDR-) pulmonary tuberculosis
(TB), and to assess the prevalence and severity of adverse events
associated with linezolid use in this patient group.
M E T H O D S
Criteria for considering studies for this review
Types of studies
To assess the efficacy of linezolid we will include randomized con-
trolled trials (RCTs) and quasi-RCTs.
To assess the prevalence and severity of adverse events associated
with the use of linezolid, we will include RCTs and quasi-RCTs,
and both prospective and retrospective cohort studies, as defined
by the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011b), where some participants receive linezolid and
others do not.
Types of participants
Adults and children with a diagnosis of multidrug-resistant
(MDR-) or extensively drug-resistant (XDR-) pulmonary tuber-
culosis (TB).
Types of interventions
Intervention
Antituberculous treatment (ATT) regimens that contained line-
zolid at any dose and for any duration.
Control
ATT regimens that did not contain linezolid.
Types of outcome measures
These outcomemeasures are based on those specified by theWHO
for TB programme outcome reporting in MDR- and XDR-TB
(WHO 2013).
Primary outcomes
• All-cause death: all deaths that occurred during each
included study and until the end of follow-up.
• TB-associated death: all deaths attributed to TB by the
study investigators that occurred during each study and until the
end of follow-up.
• Treatment failure: participants who did not show sputum
culture conversion by the end of the intensive phase of ATT, or
who had reverted from culture negative to culture positive, or
who had failed to respond clinically to treatment as defined by
the study investigators.
• Cure: participants who completed ATT as planned without
evidence of failure and had at least three consecutive negative
sputum cultures in specimens taken at least 30 days apart after
the intensive phase of treatment.
Secondary outcomes
• Treatment interrupted (default): participants who stopped
taking ATT for one month or more at any point in the course of
treatment.
• Treatment completed: participants who completed ATT as
planned but did not have at least three consecutive negative
sputum cultures in specimens taken at least 30 days apart after
the intensive phase of treatment..
• Time to sputum culture conversion: the length of time
between starting treatment and conversion from sputum culture
positive to sputum culture negative.
Adverse events
• All adverse events.
• All serious adverse events.
• Adverse events that led to discontinuation of
antituberculous drugs or dose reduction.
• Adverse events attributed to linezolid, particularly
peripheral and optic neuropathy, anaemia, thrombocytopenia,
lactic acidosis, and serotonin syndrome.
Search methods for identification of studies
Wewill attempt to identify all relevant trials regardless of language
or publication status (published, unpublished, in press, and in
progress).
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Electronic searches
We will search the following databases for relevant studies: the
Cochrane Infectious Diseases Group Specialized Register; the
Cochrane Central Register of Controlled Trials (CENTRAL)
published in the Cochrane Library; MEDLINE (PubMed); Em-
base (OVID); and LILACS, using the search terms detailed in
Appendix 1. We will also check the WHO International Clini-
cal Trials Registry Platform (WHO ICTRP; www.who.int/ictrp/
en/) and ClinicalTrials.gov (https://clinicaltrials.gov/ct2/home)
for ongoing trials using the terms: “linezolid” and “tuberculosis”.
Searching other resources
Wewill also contact researchers in the field to identify unpublished
or ongoing trials.
Data collection and analysis
Selection of studies
Two review authors (BS andDC)will screen the titles and abstracts
of the search results independently and code them as either ’re-
trieve’ (eligible or potentially eligible/unclear) or ’do not retrieve’.
We will retrieve the full-text study reports of all potentially eli-
gible studies and two review authors (BS and DC) will indepen-
dently screen them for inclusion and will record the reasons for
exclusion of ineligible studies. We will resolve any disagreement
through discussion or, if required, we will consult a third review
author. We will identify and exclude duplicates and collate multi-
ple reports of the same study so that each study, rather than each
report, is the unit of interest in the review. We will contact study
authors for clarification if a study’s eligibility is unclear. We will
resolve any disagreements through discussion and list the excluded
studies and the reasons for their exclusion in the ’Characteristics
of excluded studies’ table. We will record the selection process in
sufficient detail to complete a PRISMA flow diagram.
Data extraction and management
We will design and pilot a data extraction form, and modify the
form based on the results of the pilot. Two review authors (BS
andDC) will independently extract data from each included study
using the finalized data extraction form. BS and DC will compare
the extracted data to identify any possible errors, and will resolve
any discrepancies through discussion and by referring to the orig-
inal study articles. We will extract the following data from each
included study.
• Country and clinical setting, start and end dates of the
study, study design, inclusion and exclusion criteria applied,
number of participants eligible for inclusion and number of
participants allocated to each group.
• Participant characteristics: age, sex, history of previous TB
treatment, known contact with MDR-TB patient, duration of
symptoms at presentation, comorbidity (human
immunodeficiency virus (HIV) infection, other
immunosuppression and other diseases), diagnostic methods
used (for example, culture-based drug susceptibility testing,
Xpert MTB/RIF, line probe assay for drug susceptibility), drug
susceptibility profile of participants at entry to the study.
• Intervention data: description of drugs, dose, route of
administration in both the intensive and continuation phase,
and duration of all drugs for both phases. Administration of
other drugs or therapeutic procedures, including surgery.
Primary outcomes
For the primary outcomes we will extract the following data.
All-cause death
• Number of deaths, stratified by drug susceptibility profile,
age and HIV status, if available.
• Timing of death after start of treatment.
TB-associated death
• Number of deaths attributed to TB by the investigators,
stratified by drug susceptibility profile, age and HIV status, if
available.
Treatment failure
• Number of participants who have not shown sputum
culture conversion by the end of the intensive phase of ATT,
stratified by drug susceptibility profile, age and HIV status, if
available.
• Number of participants who have reverted from culture
negative to culture positive, stratified by drug susceptibility
profile, age and HIV status, if available.
• Number of participants who have failed to respond
clinically to treatment as defined by the investigators, stratified
by drug susceptibility profile, age and HIV status, if available.
• Method of monitoring treatment and defining treatment
failure.
• Time between start of treatment and treatment failure.
• Outcome following classification as treatment failure.
Cure
• Number of participants who have completed ATT as
planned and have had at least three negative sputum cultures in
specimens taken at least 30 days apart during the last months of
treatment, stratified by drug susceptibility profile, age, and HIV
status, if available.
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Secondary outcomes
For the secondary outcomes we will extract the following data.
Treatment interrupted
• Number of participants who stopped taking ATT for one
month or more at any point in the course of treatment, stratified
by drug susceptibility profile, age and HIV status, if available.
• Method of monitoring treatment adherence.
• Reasons for treatment interruption, if available.
Treatment completed
• Number of participants who completed ATT as planned
but did not have at least three negative sputum cultures in
specimens taken at least 30 days apart during the last months of
treatment.
• Method of monitoring treatment.
Time to sputum culture conversion
• Time between starting treatment and conversion from
sputum culture positive to sputum culture negative.
• Method of monitoring treatment, including frequency of
sputum sampling.
Follow-up
Length of follow-up, follow-up methods, number and character-
istics of losses to follow-up.
Adverse events
We will extract information on the total number of the following.
• Adverse events.
• Serious adverse events.
• Participants experiencing adverse events.
• Adverse events that led to discontinuation of
antituberculous drugs or dose reduction.
• Adverse events that attributed to linezolid, particularly
peripheral and optic neuropathy, anaemia, thrombocytopenia,
lactic acidosis, and serotonin syndrome.
For each outcome, we will extract the number of participants as-
signed and the number of participants analysed in each treatment
group. For dichotomous outcomes, we will extract the number of
participants who experienced the event. For count data outcomes,
we will extract the number of events in the intervention and con-
trol group.
Assessment of risk of bias in included studies
For randomized controlled trials (RCTs) and quasi-RCTs, two re-
view authors will independently assess the methodological qual-
ity of each included trial using the Cochrane ’Risk of bias’ tool
and report the results in a ’Risk of bias’ table (Higgins 2011a).
We will resolve any disagreements through discussion. Regarding
generation of allocation sequence and allocation concealment, we
will classify each as either adequate, inadequate, or unclear in each
included trial according to Jüni 2001. We will report who was
blinded in each included trial, and we will assess the risk of bias
associated with blinding separately for each primary outcome. If
at least 90% of participants were followed up to the trial’s com-
pletion we will classify inclusion of all randomized participants as
adequate; otherwise we will classify inclusion as inadequate. We
will attempt to contact the trial authors if information is unspec-
ified or unclear.
For non-randomized studies, we will use the ROBINS-I risk of
bias tool (Sterne 2016), and will adapt and pilot it before we use it
to assess all included non-randomized studies. The following are
areas of confounding that we expect to be relevant to all or most
included studies.
• Extent of drug resistance: number of effective drugs
available.
• Severity of TB disease at start of treatment.
• HIV co-infection.
• Timing of addition of linezolid to the regimen.
• Duration of linezolid treatment.
• Background antituberculous therapy regimen.
• Supportive care available in study setting.
Measures of treatment effect
We will use relative risk as the measure of treatment effect for
analysis.
Unit of analysis issues
Wedo not anticipate that any cluster-RCTs will meet the inclusion
criteria of the review.
For multi-armed studies, where we wish to include more than one
intervention study arm, we will split the control group to avoid
including the same participants more than once.
Dealing with missing data
The primary analysis is an intention-to-treat analysis where all
participants randomized to treatment are included in the denom-
inator. This analysis assumes that all losses to follow-up have good
outcomes. We will carry out a sensitivity analysis to explore the
impact of the missing data on the summary effect estimate for all-
cause death and cure.
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Assessment of heterogeneity
We will assess heterogeneity by visually inspecting the forest plots
to determine closeness of point estimates with each other and
overlap of confidence intervals (CIs). We will use the Chi² test
with a P value of 0.10 to indicate statistical significance, and the
I² statistic to assess heterogeneity with a value of 50% taken to
indicate significant statistical heterogeneity.
Assessment of reporting biases
We will conduct visual inspection of the funnel plot of the trials
for any obvious asymmetry that could be evidence of publication
bias.
Data synthesis
Using Review Manager 5 (RevMan 5) (RevMan 2014), we will
perform a meta-analysis on the data in included trials. We will not
combine data from RCTs and non-RCTs. As we anticipate signif-
icant variability in the samples of participants across the differ-
ent studies, we will use a random-effects model for meta-analysis,
unless there is a very small number of included studies with low
heterogeneity, in which case we will use a fixed-effect model.
For non-randomized data, wewill not perform ameta-analysis.We
will report these data descriptively in a table that includes how the
data is collected, and the reported outcomes (unadjusted). If the
study authors have adjusted data, wewill provide this estimate with
a short description of the adjustments the study authors made.
We will assess the certainty of the evidence using the Grading
of Recommendations Assessment, Development and Evaluation
(GRADE) approach. We will use GRADEpro GDT software to
construct ’Summary of findings’ tables (GRADEpro GDT 2014).
Subgroup analysis and investigation of heterogeneity
We plan to investigate heterogeneity through the following sub-
group analyses.
• Drug resistance profile, determined by: (a) % XDR, (b) %
fluoroquinolone-resistant (resistant to any fluoroquinolone, but
susceptible to injectables), (c) % injectable-resistant (resistant to
any injectable, but susceptible to fluoroquinolones).
• HIV status (seropositive and seronegative).
• Age (adults and children).
• Daily dose of linezolid (600 mg or less and over 600 mg
adult equivalent).
• Duration of linezolid (six months or less and longer than six
months).
• Total cumulative dose of linezolid.
• Other drugs within the background antituberculous drug
regimen.
Sensitivity analysis
We will perform a worst-case scenario analysis by imputing the
missing data as poor outcomes in the linezolid group and good
outcomes in the control group, and by comparing this to an avail-
able-case analysis to explore the effect of missing data on the pri-
mary outcomes all-cause death and cure.
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A P P E N D I C E S
Appendix 1. Search strategy
Search set CIDG SR CENTRAL MEDLINE Embase LILACS
1 Tuberculosis OR TB Tuberculosis OR TB
ti, ab
Tuberculosis OR TB
ti, ab
Tuberculosis OR TB
ti, ab
Tuberculosis OR TB
2 Multi-drug resistant drug resist* ORMDR
OR DR OR XDR ti,
ab
drug resist* ORMDR
OR DR OR XDR ti,
ab
drug resist* ORMDR
OR DR OR XDR ti,
ab
Multi-drug resistant
3 MDR-TB 1 and 2 1 and 2 1 and 2 MDR-TB
4 Drug-resistant DR-TB OR MDR-
TB OR XDR-TB ti,
ab
DR-TB OR MDR-
TB OR XDR-TB ti,
ab
DR-TB OR MDR-
TB OR XDR-TB ti,
ab
Drug-resistant
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(Continued)
5 XDR-TB Tuberculo-
sis, Multidrug-Resis-
tant“[Mesh] OR ”Ex-
tensively Drug-Resis-
tant
Tuberculosis“[Mesh]
Tuberculo-
sis, Multidrug-Resis-
tant”[Mesh] OR “Ex-
tensively Drug-Resis-
tant
Tuberculosis”[Mesh]
Multidrug resistant
tuberculosis [Emtree]
OR “extensively drug
resistant tuberculosis”
[Emtree] OR “drug
resistant tuberculosis”
[Emtree]
XDR-TB
6 2 or 3 or 4 or 5 3 or 4 or 5 3 or 4 or 5 3 or 4 or 5 2 or 3 or 4 or 5
7 1 and 6 “Oxazolidi-
nones”[Mesh]
“Oxazolidi-
nones”[Mesh]
Linezolid ti, ab OR
“Linezolid” [Emtree]
1 and 6
8 linezolid “linezolid” [Supple-
mentary Concept]
“linezolid” [Supple-
mentary Concept]
LZD OR Zyvox ti, ab linezolid
9 7 and 8 Linezolid OR LZD
OR Zyvox ti, ab
Linezolid OR LZD
OR Zyvox ti, ab
“oxazolidinone
derivative” [Emtree]
7 and 8
10 - 7 or 8 or 9 7 or 8 or 9 7 or 8 or 9 -
11 - 6 and 10 6 and 10 6 and 10 -
12 - - Limit 11 to Humans Limit 11 to Human -
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